“Direct assessment of in vivo target engagement assists decision-making throughout the clinical phases of drug development.”
Olof Eriksson
Director PET Imaging
First-in-class PET tracer for the glucagon receptor
Antaros Medical – Publications
“Direct assessment of in vivo target engagement assists decision-making throughout the clinical phases of drug development.”
Olof Eriksson
Director PET Imaging
Type 2 diabetes affects over 400 million people worldwide (WHO 2019). Although significant advances have been made in diabetes medicine there remains substantial unmet medical need. For new candidate drugs, it is necessary to have tools to investigate novel mechanisms of actions, efficacy and tissue distribution in order to guide development programme strategies or to differentiate against competition. In addition, complexity is increasing with e.g. dual or trigonal agonists that bind several targets with different but also overlapping biological effects. Therefore, sophisticated solutions are required for studying target engagement in clinical trials.